Work

The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: Objective.To compare the urate-lowering efficacy and the safety of febuxostat, allopurinol and placebo in Korean patients with gout for 4 weeks.Methods.Subjects (n=182) with gout were randomized to febuxostat (40, 80, 120 mg), allopurinol 300 mg, or placebo group.The primary end point was the proportion of subjects whose serum urate concentration fell to less than 6.0 mg/dL after the 4-week treatment.Results.The primary end point was reached at 25.7%, 80.0% and 83.3% of patients receiving 40, 80 and 120 mg of febuxostat, respectively, 58.3% of those receiving 300 mg of allopurinol and none of the placebo (p＜0.001: each febuxostat dose or allopurinol group versus placebo group, p=0.0484 and p=0.0196: febuxostat 80 and 120 mg compared with allopurinol, respectively).The number and proportion of subjects who developed adverse events (AEs) were 13 subjects (37%), 14 (39%) and 18 (50%) in the febuxostat of 40, 80 and 120 mg group, respectively, 21 (57%) in the allopurinol 300 mg group and 17 (46%) in the placebo group.No statistically significant differences in the incidence rates of adverse events were observed between the groups.There was no significant difference in gout flare-up incidence.Conclusion.Febuxostat, 80 mg or 120 mg, was more effective than allopurinol (300 mg) or placebo, when lowering the serum urate.The safety of febuxostat and allopurinol was comparable.

Source: Journal of Rheumatic Diseases

DOI: 10.4078/jrd.2013.20.4.223